Press release
Cirrhosis Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Key Takeaways from the Cirrhosis Pipeline Report
* DelveInsight's Cirrhosis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Cirrhosis treatment.
* The leading companies working in the Cirrhosis Market include GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
* Promising Cirrhosis Pipeline Therapies in the various stages of development include NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.
* April 2024:- Healthgen Biotechnology Corp.- A Phase 3 Randomized, Double-blind, Active-controlled Multi-center Study to Evaluate the Efficacy, Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia. The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA. The main question it aims to answer is whether OsrHSA is effective in elevating the serum albumin level of cirrhotic patients with hypoalbuminemia.
Request a sample and discover the recent advances in Cirrhosis Treatment Drugs @ Cirrhosis Pipeline Report [https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight]
The Cirrhosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Cirrhosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Cirrhosis clinical trial landscape.
Cirrhosis Overview
Cirrhosis is scarring (fibrosis) of the liver caused by long-term liver damage. The scar tissue prevents the liver working properly. Cirrhosis is sometimes called end-stage liver disease because it happens after other stages of damage from conditions that affect the liver, such as hepatitis.
Find out more about Cirrhosis Treatment Drugs @ Drugs for Cirrhosis Treatment [https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight]
Cirrhosis Emerging Drugs Profile
* GXHPC 1: GWOXI Stem Cell Applied Technology
* LPCN 1148: Lipocine
* Belapectin: Galectin Therapeutics
Cirrhosis Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Cirrhosis. The Cirrhosis companies which have their Cirrhosis drug candidates in the most advanced stage, i.e. phase II/III include, Galectin Therapeutics.
Learn more about the emerging Cirrhosis Pipeline Therapies @ Cirrhosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight]
Scope of the Cirrhosis Pipeline Report
* Coverage- Global
* Cirrhosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cirrhosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Cirrhosis Companies- GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
* Cirrhosis Pipeline Therapies- NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.
Dive deep into rich insights for new drugs for Cirrhosis Treatment, Visit @ Cirrhosis Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight]
Table of Content
* Introduction
* Executive Summary
* Cirrhosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cirrhosis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase II/III)
* Belapectin: Galectin Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* GXHPC 1: GWOXI Stem Cell Applied Technology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Cirrhosis Key Companies
* Cirrhosis Key Products
* Cirrhosis- Unmet Needs
* Cirrhosis- Market Drivers and Barriers
* Cirrhosis- Future Perspectives and Conclusion
* Cirrhosis Analyst Views
* Cirrhosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cirrhosis-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cirrhosis Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) here
News-ID: 3496497 • Views: …
More Releases from ABNewswire
Manhattan, NY Condo Real Estate Attorney Peter Zinkovetsky Highlights Legal Risk …
Buying a new construction condominium in New York City can be appealing, but the process is filled with legal complexity that many buyers underestimate. Manhattan, NY condo real estate attorney Peter Zinkovetsky of Avenue Law Firm (https://www.avenuelawfirm.com/buying-a-new-construction-condo-in-nyc-5-legal-risks-to-avoid/) explains that new development purchases differ sharply from resales because contracts are drafted by sponsors and often include terms that favor the developer. These agreements can lock buyers into long timelines, unexpected costs,…
Little Rock Child Injury Claims Lawyer Joseph Gates Discusses Daycare Negligence …
When a child is injured due to daycare negligence, families are often left shocked, overwhelmed, and unsure where to turn. These injuries frequently occur in situations that could have been prevented, and the emotional and financial toll can be long-lasting. Little Rock child injury claims lawyer Joseph Gates of Gates Law Firm, PLLC (https://www.gateslawpllc.com/standard-of-care-and-proving-negligent-supervision-in-arkansas/), discusses how Arkansas law addresses these cases and what families should know if they believe a…
Retail Data Analytics: New Retlia Market Brief Warns Retail Is "On a Knife's Edg …
"Boy that abyss is sure creeping closer." Retlia released the Jan 12, 2026 edition of The Register, a retail data market brief analyzing headline sentiment and retail indicators. The report finds that while retail demand remains intact, momentum is slowing, manufacturing contraction is deepening, and the retail sector in a fragile position entering 2026. The brief is designed to help retail executives interpret economic signals, inventory risk, and margin pressure…
A Silk Press Workshop Focused on Technique and Hair Health
Luv Your Hair Studio, a natural hair salon in Atlanta, is hosting an Atlanta Silk Press Class on February 22 at 1:00 PM, led by Shynethia. This hands-on training is for hairstylists, salon owners, and at-home learners who want a step-by-step silk press process focused on technique, heat control, and healthy hair results. The class covers prep, blow-drying, flat iron technique, and professional finishing. Pricing is $275 and space is…
More Releases for Cirrhosis
Cirrhosis Pipeline: Novel Antifibrotic Therapies and Regenerative Approaches Red …
The treatment landscape for cirrhosis, a progressive liver condition marked by fibrosis and compromised liver function, is witnessing a transformative shift as biopharmaceutical companies advance beyond symptomatic management to target the underlying causes of liver damage. With no approved therapies to reverse established fibrosis, there is a growing focus on antifibrotic agents, hepatoprotective compounds, and regenerative therapies that aim to halt or reverse disease progression. Companies like Ocera Therapeutics, Gilead…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known as fibrosis as a result of liver disease damage. Cirrhosis is caused by alcoholic liver disease, non-alcoholic steatohepatitis (NASH), chronic hepatitis B, and chronic hepatitis C.
To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31149
Cirrhosis symptoms emerge slowly until liver…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about Primary Biliary Cirrhosis - Drug Pipeline here: https://www.globalinsightservices.com/reports/primary-biliary-cirrhosis-primary-biliary-cholangitis-drug-pipeline-landscape-2022/
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Liver Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about this report: https://www.globalinsightservices.com/reports/liver-cirrhosis-drug-pipeline-landscape-2023/
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.
Read more about Primary Biliary Cirrhosis - Drug Pipeline…
Global Liver Cirrhosis Market Growth 2018-2023
Market Research Report Store offers a latest published report on Liver Cirrhosis Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Liver Cirrhosis players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Liver Cirrhosis with respect to individual…
